Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2011

View Archived Issues

Phase III briakinumab data analyzed

Scientists at Astellas Pharma synthesize novel plasma kallikrein inhibitors

Phase II studies assess NGR-hTNF in lung and ovarian cancer

Novel TRPV4 antagonists prepared by researchers at GlaxoSmithKline

Phase III trial of cabozantinib meets primary endpoint

RetroSense Therapeutics licenses gene therapy from Wayne State University

EMA begins new review of Protelos and Osseor

Qutenza shows efficacy in HIV-associated neuropathy

New data presented from CARE-MS trials of alemtuzumab

Novel omega-3 MUFAs show oncolytic potential

Precision Antibody receives FDA contract to develop potency assays for influenza vaccine

TiGenix moves into randomized recruitment stage in phase Ia/IIb Cx-611 study

Merck Frosst discloses new HIV reverse transcriptase inhibitors

California Stem Cell acquires stem cell therapy program for metastatic melanoma

Basilea finishes multiple-ascending-dose study of antibiotic BAL-30072

Italian researchers prepare novel TRPV1 antagonists

New glucagon receptor antagonists designed by Merck & Co.

CDC advisory committee recommends Merck & Co.'s HPV vaccine for boys and young men

Lilly withdraws Xigris worldwide following PROWESS-SHOCK study

Bayer's phase III CORRECT trial meets primary endpoint

Elusys initiates new human safety study of anthrax treatment candidate

FDA provides update on safety review of Chantix

FDA grants IND clearance for phase II trial of Aeterna Zentaris' AEZS-108 in breast cancer

Seattle Genetics starts new Adcetris trial in nonlymphoma malignancies

DelMar Pharmaceuticals commences phase I/II trial of VAL-083

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...